Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
In vitro cell culture study of a novel composite material showing dose-dependent cytotoxicity and morphological effects, without efficacy comparison, animal validation, or clinical translation.
This is a narrative review synthesizing preclinical and early-stage evidence on green-synthesized nanomaterials for kidney cancer, raising mechanistic questions rather than reporting clinical trial data or definitive efficacy.
A sound single-centre in vitro study showing a real conjugate chemistry result—reduced cardiomyocyte toxicity with retained HER2+ cancer activity—but limited to spheroid models, surrogate endpoints, and acute exposure without clinical translation or mechanistic validation.
Preclinical study in murine tumor model with surrogate endpoints (macrophage polarization, cytokine profile, cardiac markers) and no human data; promising mechanistic approach but requires clinical validation.
Preclinical proof-of-concept study in cell and mouse models of a novel nanoparticle platform; no human data, efficacy metrics lack quantitative comparison to standard therapy, and no phase 1 translation reported.
A narrative review synthesizing preclinical mechanistic work and emerging nanoplatform designs, not reporting original clinical or trial data, and explicitly stating that clinical translation remains challenged and further studies are required.
Preclinical proof-of-concept study demonstrating a novel nanoplatform mechanism in cell and animal models, without human efficacy data or direct comparison to standard therapy.
Preclinical study demonstrating a novel nanomaterial design with in vitro and in vivo efficacy in cancer models, but lacking clinical translation, mechanistic validation in human tissue, or comparison to standard therapies.